Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Leases (2019 - 2025)

Tg Therapeutics has reported Current Leases over the past 7 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Current Leases at $1.0 million for Q4 2025, down 9.77% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 9.77% YoY), and the annual figure for FY2025 was $1.0 million, down 9.77%.
  • Current Leases for Q4 2025 was $1.0 million at Tg Therapeutics, down from $1.1 million in the prior quarter.
  • Over the last five years, Current Leases for TGTX hit a ceiling of $1.6 million in Q3 2022 and a floor of $1.0 million in Q4 2025.
  • Median Current Leases over the past 5 years was $1.5 million (2021), compared with a mean of $1.4 million.
  • Biggest five-year swings in Current Leases: rose 10.08% in 2022 and later decreased 19.99% in 2024.
  • Tg Therapeutics' Current Leases stood at $1.4 million in 2021, then rose by 10.02% to $1.6 million in 2022, then fell by 8.54% to $1.4 million in 2023, then decreased by 19.99% to $1.2 million in 2024, then decreased by 9.77% to $1.0 million in 2025.
  • The last three reported values for Current Leases were $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.